Trial Profile
Phase 2, Parallel-Arm Study of MGCD265 in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer With Activating Genetic Alterations in Mesenchymal-Epithelial Transition Factor
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Glesatinib (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- Acronyms AMETHYST
- Sponsors Mirati Therapeutics
- 11 Feb 2019 Status changed from active, no longer recruiting to completed.
- 16 Nov 2018 Results evaluating whether high MET mutant Allele Frequency of METex14 predicts tumor response to glesatinib from 265-109 and 265-101, presented at the 30th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics.
- 17 Aug 2018 Planned End Date changed from 1 Jan 2019 to 1 Dec 2018.